Contemporary Trends in Axillary Surgery for ER-Positive, HER2-Negative Breast Cancer Stratified by Neoadjuvant Endocrine Therapy, Neoadjuvant Chemotherapy, or Upfront Surgery.

ABSTRACT:

Background

De-escalation of axillary surgery for hormone receptor-positive breast cancer has gained traction, but guidelines for axillary management after neoadjuvant endocrine therapy (NET) remain ill-defined.

Methods

Female patients age ≥50 years with clinical T1-4c, N0-1, ER+/HER2- breast cancer (2012-2021) were selected from the National Cancer Database (NCDB) and divided into three groups based on treatment: upfront surgery, neoadjuvant chemotherapy (NAC), or NET. Axillary surgery was categorized as no axillary surgery, sentinel lymph node biopsy (SLNB) alone, sentinel lymph node biopsy followed by axillary lymph node dissection (ALND), or ALND alone. Descriptive analysis and logistic regression were used to identify factors associated with ALND, and survival anal

SUBMITTER: Douglas SR 

PROVIDER: S-EPMC12619107 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature